Characteristics and Outcome of Children with Wilms Tumor Requiring Intensive Care Admission in First Line Therapy

Anouk Steur 1, Paulien A. M. A. Raymakers-Janssen 1,2, Martin C. J. Kneyber 3, Sandra Dijkstra 3, Job B. M. van Woensel 4, Dick A. van Waardenburg 5, Cornelis P. van de Ven 1, Alida F. W. van der Steeg 1, Marc Wijnen 1, Marc R. Lilien 6, Ronald R. de Krijger 1,7, Harm van Tinteren 1,8, Annemieke S. Littooij 8, Geert O. Janssens 1, Annemarie M. L. Peek 1, Godelieve A. M. Tytgat 1, Annelies M. Mavinkurve-Grootuis 1, Martine van Grotel 1, Marry M. van den Heuvel-Eibrink 1 and Roelie M. Wösten-van Asperen 2,*

Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands; anouk.steur@gmail.com (A.S.); p.a.m.a.raymakers-janssen@umcutrecht.nl (P.A.M.A.R.-J.); c.p.vandeven-4@prinsesmaximacentrum.nl (C.P.v.d.V.); A.F.W.vanderSteeg@prinsesmaximacentrum.nl (A.F.W.v.d.S.); m.h.w.wijnen-5@prinsesmaximacentrum.nl (M.W.); r.r.dekrijger-2@prinsesmaximacentrum.nl (R.R.d.K.); h.vantinteren@prinsesmaximacentrum.nl (H.v.T.); g.o.r.janssens@umcutrecht.nl (G.O.J.); a.m.l.peek@prinsesmaximacentrum.nl (A.M.L.P.); g.a.m.tytgat@prinsesmaximacentrum.nl (G.A.M.T.); a.m.c.mavinkurve-grootuis@prinsesmaximacentrum.nl (A.M.M.-G.); M.vanGrotel@prinsesmaximacentrum.nl (M.v.G.); m.m.vandenheuvel-eibrink@prinsesmaximacentrum.nl (M.M.v.d.H.-E.)

Department of Pediatric Intensive Care, Wilhelmina Children’s Hospital/University Medical Center Utrecht, 3584 EA Utrecht, The Netherlands

Division of Pediatric Critical Care Medicine, Beatrix Children’s Hospital/University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; m.c.j.kneyber@umcg.nl (M.C.J.K.); s.k.dijkstra@umcg.nl (S.D.)

Department of Pediatric Intensive Care, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands; j.b.vanwoensel@amsterdamumc.nl

Department of Pediatric Intensive Care, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands; d.van.waardenburg@ummc.nl

Department of Pediatric Nephrology, Wilhelmina Children’s Hospital/University Medical Center Utrecht, 3584 EA Utrecht, The Netherlands; m.lilien@umcutrecht.nl

Department of Pathology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands

Department of Radiology, Wilhelmina Children’s Hospital/University Medical Center Utrecht, 3584 EA Utrecht, The Netherlands; A.S.Littooij-2@umcutrecht.nl

Correspondence: r.m.vanasperen@umcutrecht.nl

Simple Summary: Survival of children with Wilms tumor is excellent. However, treatment-related complications may occur, requiring treatment at the pediatric intensive care unit (PICU). The aim of our retrospective study was to assess the frequency, clinical characteristics, and outcome of 175 children with Wilms tumor requiring treatment at the PICU in the Netherlands. Thirty-three patients (almost 20%) required unplanned PICU admission during their disease course. Younger age at diagnosis, intensive chemotherapy regimens, and bilateral tumor surgery were risk factors for these unplanned PICU admissions. Three children required renal replacement therapy, two of which continued dialysis after PICU discharge. Two children died during their PICU stay. During follow up, hypertension and renal dysfunction were frequently observed, which justifies special attention for kidney function and blood pressure monitoring during and after treatment of these children.

Abstract: Survival rates are excellent for children with Wilms tumor (WT), yet tumor and treatment-related complications may require pediatric intensive care unit (PICU) admission. We assessed the frequency, clinical characteristics, and outcome of children with WT requiring PICU admissions in a multicenter, retrospective study in the Netherlands. Admission reasons of unplanned PICU admissions were described in relation to treatment phase. Unplanned PICU admissions were compared to a control group of no or planned PICU admissions, with regard to patient characteristics and short and long term outcomes. In a multicenter cohort of 175 children with an underlying WT, 50 unplanned PICU admissions were registered in 33 patients. Reasons for admission were diverse
and varied per treatment phase. Younger age at diagnosis, intensive chemotherapy regimens, and bilateral tumor surgery were observed in children with unplanned PICU admission versus the other WT patients. Three children required renal replacement therapy, two of which continued dialysis after PICU discharge (both with bilateral disease). Two children died during their PICU stay. During follow-up, hypertension and chronic kidney disease (18.2 vs. 4.2% and 15.2 vs. 0.7%) were more frequently observed in unplanned PICU admitted patients compared to the other patients. No significant differences in cardiac morbidity, relapse, or progression were observed. Almost 20% of children with WT required unplanned PICU admission, with young age and treatment intensity as potential risk factors. Hypertension and renal impairment were frequently observed in these patients, warranting special attention at presentation and during treatment and follow-up.

**Keywords:** Wilms tumor; intensive care; pediatric oncology; risk factors; outcome

### 1. Introduction

Childhood renal tumors account for approximately 6% of all pediatric malignancies [1]. The majority of these tumors are Wilms tumors (WT). Although advances in treatment strategies have led to an excellent outcome for children with localized WT, future challenges lie in improving survival of specific subgroups and decreasing direct as well as late toxic effects of treatment [2–6]. These treatment-related toxicities can require admission to the pediatric intensive care (PICU). However, the prevalence and risk factors of critical illness at presentation and during treatment, and its outcome have not been studied intensively. In general, children with cancer requiring PICU admission represent a highly complex and challenging group, with a survival inferior to that of the general PICU population [7]. Case reports confirm that children with WT may require unplanned intensive care treatment due to various tumor- and treatment-related emergencies. These cases revealed not only relatively well-known emergencies associated with WT at presentation, such as malignant hypertension and extensive (intracardial) tumor thrombus, but also postoperative hemorrhage, cardiomyopathy and hepatotoxicity, intracranial bleeding, and seizures [8–18].

In view of the scarce available data on PICU admissions of patients with WT, we conducted a retrospective, multicenter observational cohort study to describe the frequency, clinical characteristics, and outcomes of PICU admissions in children with an underlying WT in the Netherlands.

### 2. Materials and Methods

#### 2.1. Study Design

We conducted a retrospective cohort study of Dutch patients diagnosed with WT and treated in one of the five participating Dutch tertiary care hospitals from January 2003 to January 2019. After January 2015, all cases were diagnosed and treated in the national pediatric oncology center, the Princess Máxima Center for Pediatric Oncology, in Utrecht, the Netherlands. We included only subjects with a primary WT, aged <18 years at diagnosis, who gave consent for registration in the International Pediatric Oncology Society Renal Tumour Study Group (SIOP-RTSG) Registry and/or the Princess Máxima Center Data & Biobank Registry. Patients with a non-WT renal tumor were excluded from the current analysis.

#### 2.2. Data Collection

Baseline, diagnostic, treatment, and outcome data were collected for all included patients. Baseline characteristics included demographic variables such as gender and age at diagnosis. Disease stage was documented, in which metastasized WT patients at diagnosis were included in the stage IV group regardless of local abdominal stage. The histological diagnosis was classified as low, intermediate, or high risk according to the revised SIOP
working classification of Renal Tumours of Childhood 2001 [19]. Diffuse anaplastic and blastemal predominant histological types were documented as high-risk WTs. The presence of a congenital or genetic anomaly was defined as the presence of either one or more congenital malformations and/or dysmorphic features, or a confirmed genetic germline aberration and/or confirmed syndrome. Isolated skin lesions, such as café-au-lait macules or solitary hemangiomas, were not classified as a congenital malformation in this study.

Details on treatment were retrieved from the medical records. Preoperative chemotherapy was classified as none (upfront tumor surgery), AV (4-week regimen containing vincristine and actinomycin), AVD (6-week regimen containing vincristine, actinomycin, and doxorubicin), or in exceptional cases >3 drugs (any regimen containing more than three chemotherapeutic agents). Surgical treatment variables included renal surgery type (tumor nephrectomy or nephron sparing surgery), tumor thrombectomy and/or metas-
tectomy, performed as part of the first-line treatment, as described in the corresponding surgical report.

Postoperative chemotherapy regimens were classified as none, vincristine, AV-1 (≤5-week regimen containing vincristine and actinomycin), AV-2 (27-week regimen containing vincristine and actinomycin), AVD (regimen containing vincristine, actinomycin, and doxorubicin) and >3 drugs (any regimen containing more than three chemotherapeutic agents). We documented whether postoperative radiotherapy was administered, as well as the applied radiotherapy dose and field.

For each PICU admission, additional data were collected, including time from WT diagnosis to PICU admission, treatment phase at PICU admission, indication for PICU admission, and pediatric index of mortality (PIM2) score at PICU admission [20]. The treatment phase at PICU admission was categorized into the following phases: diagnostic (prior to administration of any form of oncological treatment), preoperative chemotherapy, renal tumor surgery, postoperative treatment (chemotherapy and/or radiotherapy), and follow-up (≥1 week after the completion of WT treatment). Indications for PICU admission were categorized as postoperative monitoring, respiratory failure, circulatory failure, sepsis, neurological failure, kidney injury, or other.

2.3. Outcomes

The primary outcome was the frequency of unplanned PICU admissions during first line therapy and follow-up. A planned PICU admission was defined as postoperative monitoring following planned diagnostics under anesthesia or surgery. All other indications for PICU admission were deemed unplanned PICU admissions. Secondary outcomes included PICU length of stay (LOS), use of PICU resources (respiratory support, vasopressor and/or inotropic support, extracorporeal membrane oxygenation (ECMO), inhaled nitric oxide, and continuous renal replacement therapy (CRRT)), PICU mortality, overall mortality, disease outcome variables, and cardiac and renal morbidity at end of oncological treatment and last follow-up.

Disease outcome variables were relapse and progression (including site and subsequent treatment), death, or survival. In case of death, the following variables were recorded: cause of death (categorized as tumor-related, treatment-related, unrelated, or unknown) and time between WT diagnosis and death. The International Pediatric Oncology Mortality Classification Group (IPOMCG) definition of treatment-related mortality was used [21].

Cardiac morbidity was defined as left-ventricular shortening fraction < 28% confirmed by cardiac ultrasound and/or on active treatment by cardiologist for cardiomyopathy. Variables regarding renal morbidity were hypertension, renal function impairment, and use of renal replacement therapy (RRT) including renal transplantation. The presence of hypertension was defined as three consecutive blood pressure measurements ≥95th percentile for age according to the American Academy of Pediatrics clinical practice guideline and/or the use of antihypertensive medication [22]. If blood pressure measurements were not performed or documented, and the patients did not receive antihypertensive treatment, this was classified as absence of hypertension. The presence of chronic kidney
disease (CKD) was defined according to the Kidney Disease: Improving Global Outcome (KDIGO) classification: i.e., estimated glomerular filtration rate (GFR) category < 90 mL/min/1.73 m² and/or the presence of proteinuria, defined as an albumin/creatinine ratio ≥3 mg/mmol [23].

2.4. Statistical Analysis

The clinical characteristics and outcomes of WT patients with unplanned PICU admissions were compared to children without or with planned PICU admissions only. These latter two groups together represented the control group.

Categorical variables were displayed as frequencies (%) and compared using chi-square or Fisher exact test. Normality was tested with the Kolmogorov–Smirnov test. Continuous variables were displayed as medians with interquartile ranges (IQRs) and were compared with the Wilcoxon rank-sum test. Outcome of cardiac and renal morbidity at end of oncological treatment and last follow-up were compared with Jonckheere trend test. Data analysis was generated using SPSS version 25 (IBM, Armonk, NY, USA).

3. Results

3.1. Study Population

A total of 256 children with a renal tumor who were treated in one of the five participating tertiary care centers between 1 January 2003 and 1 January 2019 were registered in the SIOP-RTSG NL Registry and/or the Princess Máxima Center Data & Biobank Registry. Of those, 69 children were excluded because of a histological diagnosis not concordant with WT, and four were excluded because of an age older than 18 years at diagnosis. For six patients, there was insufficient information available to allow medical chart review. Two patients were excluded as they had been admitted to PICU only during relapse treatment leaving a total of 175 included patients (Figure 1).

Seventy-eight WT patients (45%) were admitted at least once to PICU during their treatment, resulting in 120 PICU admissions in this patient group, including 50 unplanned PICU admissions (42%) and 70 planned PICU admissions (58%).

3.2. Characteristics of Patients Requiring PICU Admission

Baseline characteristics of patients requiring unplanned PICU admissions versus the control group are described in Table 1. Thirty-three children with WT required unplanned PICU admission during the course of first-line treatment and follow-up (19%). Patients with an unplanned PICU admission were significantly younger, had received more intensive
chemotherapy regimens, and presented more often with bilateral tumors when compared to patients with only planned or no PICU admissions (control group) (Table 1). No significant differences were found in other disease stage, metastases, and histology between patients with unplanned PICU admissions and the control group.

3.3. Indications for Unplanned PICU Admissions per Treatment Phase

Of the 50 unplanned PICU admissions, in 33 unique patients (nine patients were admitted twice and four patients were admitted three times), 12 occurred in the diagnostic phase (11 patients), 6 during pre-operative chemotherapy (6 patients), 15 after renal tumor surgery (14 patients), 16 during the postoperative treatment phase (11 patients), and 1 during follow-up (1 patient) (Figure 2 and Table 2). Indications for these admissions consisted primarily of respiratory and/or circulatory failure in all treatment phases.

Figure 2. Indications for unplanned PICU admissions in children with WT per treatment phase.

Table 1. Baseline characteristics.

|                      | Total Population $n = 175$ Patients | Control Group (No PICU Admission or Planned PICU Admission Only) $n = 142$ Patients | Unplanned PICU Admission $n = 33$ Patients |
|----------------------|-------------------------------------|----------------------------------------------------------------------------------|------------------------------------------|
| Gender, male, $n$ (%)| 82 (46.9)                           | 70 (49.3)                                                                         | 12 (36.4)                                |
| Age in months, median (IQR) | 38.5 (22.0–57.0)                   | 42.2 (27.4–61.1)                                                                 | 22.0 (13.8–38.8)                         |
| Disease stage, $n$ (%) |                                     |                                                                                  |                                          |
| I                    | 60 (34.3)                           | 53 (37.3)                                                                         | 7 (21.2)                                 |
| II                   | 35 (20.0)                           | 32 (22.5)                                                                         | 3 (9.1)                                  |
| III                  | 38 (21.7)                           | 27 (19.0)                                                                         | 11 (33.3)                                |
| IV *                 | 24 (13.7)                           | 18 (12.7)                                                                         | 6 (18.2)                                 |
| V                    | 18 (10.2)                           | 12 (8.5)                                                                          | 6 (18.2)                                 |
| *abdominal stage     | I ($n = 3$), II ($n = 3$), III ($n = 11$), V ($n = 1$) | I ($n = 1$), II ($n = 0$), III ($n = 3$), V ($n = 2$) |                                        |
Table 1. Cont.

| Metastases, n (%) | Lung | Liver | Other site | Multiple sites |
|------------------|------|-------|------------|---------------|
|                  | 17 (9.6) | 13 (9.2) | 4 (11.4) | 2 (5.8) |

| Histology, n (%) | Low risk | Intermediate risk | High risk | -Diffuse anaplasia | -Blastemal predominant | -Diffuse anaplasia and Blastemal predominant |
|------------------|----------|-------------------|-----------|-------------------|-----------------------|---------------------------------------------|
|                  | 9 (5.1) | 147 (84.0) | 19 (10.8) | 7 (4.0) | 10 (5.7) | 2 (1.1) |
|                  | 6 (4.2) | 120 (84.5) | 16 (11.3) | 6 (4.2) | 8 (5.6) | 2 (1.4) |
|                  | 3 (9.1) | 27 (81.8) | 3 (9.1) | 1 (3.0) | 2 (6.1) | 0 (0.0) |

| Documented genetic anomaly or congenital malformation, n (%) ** | Beckwith-Wiedeman syndrome | Hemihipertrophy NOS | WT1 gene variant | Genito-urinary malformation NOS | Other |
|---------------------------------------------------------------|---------------------------|-------------------|-----------------|--------------------------------|-------|
|                                                               | 5 (2.9)                  | 9 (5.1)           | 8 (4.6)         | 3 (1.7)                       | 17 (9.7) |
|                                                               | 5 (3.5)                  | 7 (4.9)           | 4 (2.8)         | 3 (2.1)                       | 11 (7.7) |
|                                                               | 0 (0.0)                  | 2 (6.1)           | 4 (12.1)        | 0 (0.0)                       | 6 (18.2) |

| Preoperative treatment, n (%) | None | AV | AVD | >3 drugs |
|------------------------------|------|----|-----|---------|
|                              | 8 (4.6) | 138 (78.8) | 24 (13.7) | 5 (2.9) |
|                              | 6 (4.2) | 116 (82.0) | 18 (13.4) | 2 (1.4) |
|                              | 2 (6.1) | 22 (66.7) | 6 (18.2) | 3 (9.1) |

| Renal surgery, n (%) | Nilateral | Bilateral | Other |
|---------------------|-----------|-----------|-------|
|                     | 156 (89.1) | 131 (92.2) | 25 (75.7) |
|                     | 11 (7.7) | 8 (24.2) | 3 (9.1) |

| Thrombectomy, n (%) | 10 (5.8) | 7 (4.9) | 3 (9.1) |
| Metastectomy, n (%) | 6 (3.4) | 4 (2.8) | 2 (6.1) |

| Postoperative treatment, n (%) | None | VCR | AV-1 | AV-2 | AVD | >3 drugs |
|-------------------------------|------|-----|------|------|-----|---------|
|                               | 5 (2.9) | 3 (1.7) | 41 (23.4) | 57 (32.6) | 38 (21.7) | 31 (17.7) |
|                               | 4 (2.8) | 2 (1.4) | 38 (28.6) | 43 (30.3) | 33 (23.2) | 22 (15.5) |
|                               | 1 (3.0) | 1 (3.0) | 3 (9.1) † | 14 (42.4) | 5 (15.2) † | 9 (27.3) † |

| Radiotherapy, n (%) | Abdominal | Pulmonary | Combined |
|---------------------|-----------|-----------|----------|
|                     | 53 (30.3) | 2 (1.1) | 6 (3.4) |
|                     | 41 (28.9) | 2 (1.4) | 3 (2.1) |
|                     | 12 (36.4) | 0 (0) | 3 (9.1) |

** Other congenital or genetic anomalies, specified: no PICU admission or planned PICU admission only: 47XXY, neurofibromatosis type 1, cystinuria, heterozygous CHEK2/MUTYH mutation, familial paraganglioma, atrial septum defect, developmental delay NOS (n = 2), dysmorphic features NOS, ventricular septal defect with subvalvar stenosis and dysmorphic features NOS (n) syndrome diagnosis was based on clinical assessment and not systematic counseling and NGS in those days unplanned PICU admission: Fanconi anemia (homozygous BRCA2-mutation), tuberous sclerosis (TSC1 mutation), chromosome 16q deletion, skeletal dysplasia NOS, antenatal WT, prematurity with macroglossia and developmental delay. IQR: interquartile range, WT: Wilms tumor, NOS: not otherwise specified, AV: dactinomycin/vincristine regimen, AVD: dactinomycin/vincristine/doxorubicin regimen, AV: ≤5 wk regimen dactinomycin/vincristine, AV-2: >5 week regimen dactinomycin/vincristine. † statistically significant difference p < 0.05.

Causes for respiratory and circulatory failure in both the diagnostic and preoperative chemotherapy phase were mainly tumor-related (Table 2). Respiratory failure was mainly due to the presence of abdominal tumor mass, with or without pulmonary metastases and accompanying pulmonary infection. Hypertension was the main cause of circulatory failure. Other causes were intra-tumor hemorrhage and one case of circulatory failure secondary to gastrointestinal obstruction caused by Wilms tumor mass. No other hemorrhages were observed. Information of paraneoplastic Von Willebrand Factor was not documented.

The majority of unplanned PICU admissions following renal tumor surgery were due to circulatory failure, most frequently caused by intraoperative abdominal hemorrhage and hypotension. PICU admission indications in the postoperative treatment phase were
more diverse and mainly treatment-related. In the one unplanned PICU admission during follow-up 34 months after discontinuation of WT treatment, the admission indication was neurological complications following preexisting scoliosis correction, hence unrelated to WT.

Table 2. Indications for unplanned PICU admissions in children with WT per treatment phase-admission indications and underlying cause per individual unplanned PICU admission.

| Clinical Characteristics (Gender, Age, Stage, Histology, History) | PICU Admission Indication | Causes Underlying PICU Admission Indication |
|---------------------------------------------------------------|--------------------------|------------------------------------------|
| **Diagnostic phase**                                          |                          |                                          |
| F, 6 mo, I, IR                                                | circulatory failure      | hypertension                             |
| M, 1.6 y, I, IR                                               | circulatory failure      | intratumoral hemorrhage                  |
| F, 6 mo, I, IR                                                | circulatory failure      | hypertension                             |
| F, 1.5 y, II, IR, Fanconi anemia                              | respiratory and circulatory failure | ARDS (suspected infection), abdominal tumor mass, hypertension |
| F, 1.6 y, II, IR                                              | circulatory failure      | hypertension                             |
| M, 6 mo, III, LR *                                           | circulatory failure      | hypertension                             |
| F, 1.8 y, III, IR *                                          | circulatory failure      | intratumoral hemorrhage                  |
| F, 0 mo, III, IR, antenatal WT *                              | respiratory and circulatory failure | antenatal abdominal tumor mass |
| (2 PICU admissions)                                           | respiratory failure      | pulmonary metastases, suspected pneumonia |
| F, 1.5 y, IV (lung, bone), IR *                               | respiratory failure      | abdominal tumor mass, pulmonary metastases |
| F, 2.3 y, IV (lung), bilateral, IR                            | respiratory failure      | abdominal tumor mass, pulmonary metastases, pleural effusion |
| **Preoperative chemotherapy phase**                           |                          |                                          |
| F, 2 mo, I, IR                                                | respiratory failure      | abdominal mass with chyloperitoneum      |
| M, 6 mo, III, LR *                                           | circulatory failure      | hypertension                             |
| F, 1.8 y, III, IR *                                          | circulatory failure      | abdominal tumor mass causing bowel obstruction |
| F, 2.5 y, III, IR                                             | circulatory failure      | hypertension                             |
| F, 3.7 y, III, IR *                                          | circulatory failure      | hypertension                             |
| M, 9 mo, V, IR, WT1 mutation                                  | respiratory failure      | abdominal tumor mass                    |
| **Renal tumor surgery**                                       |                          |                                          |
| F, 1.5 y, I, LR                                              | circulatory failure      | left TN: transection SMA                  |
| F, 1.7 y, I, IR, hemihypertrophy **                          | circulatory failure      | left NSS: intraoperative hemorrhage      |
| (2 PICU admissions)                                           | circulatory failure      | left TN: hypotension                     |
| M, 4.3 y, II, premature GA 26 wk                              | respiratory failure      | left TN: inability to wean postoperatively, BPD |
| M, 2.8 y, III, IR                                            | circulatory failure      | right TN, thrombectomy VCI / RA: hypotension |
| M, 1.5 y, III, IR, WT1 mutation                               | circulatory failure      | right TN: intraoperative hemorrhage      |
| F, 3.7 y, III, IR *                                          | circulatory failure      | right TN, partial hepatectomy, hemicolecotomy: hypotension |
| F, 2.9 y, III, IR *                                          | circulatory failure      | right TN: intraoperative hemorrhage      |
| F, 3.0 y, III, IR **                                         | respiratory failure      | right TN, partial hepatectomy: post-extubation subglottic stenosis |
| M, 2.9 y, III, IR, chr16 q deletion                           | circulatory failure      | left TN: transection SMA                  |
| F, 7.1 y, III, HR (BP) *                                     | circulatory failure      | left TN, thrombectomy VCI: intraoperative hemorrhage |
| Clinical Characteristics | PICU Admission Indication | Causes Underlying PICU Admission Indication |
|--------------------------|--------------------------|------------------------------------------|
| F, 3.2 y, IV (lung), IR, skeletal dysplasia * | circulatory failure | left TN: hypotension |
| M, 3.8 y, V, IR | circulatory failure | right TN and left NSS, day + 2: intra-abdominal urine leakage |
| F, 11 mo, V, IR, WT1 mutation | circulatory failure | left TN, right tumor biopsy: hypotension |
| F, 5.1 y, V, IR, TSC1 mutation | circulatory failure | left NSS: intraoperative hemorrhage |
| **Postoperative chemotherapy phase** | | |
| F, 1.8 y, I, LR | circulatory failure | urosepsis (Citrobacter spp.) |
| F, 1.7 y, I, IR, hemihypertrophy ** | respiratory failure, kidney injury | kidney injury (acute on chronic) with fluid overload, ascites, suspected infection |
| M, 2.9 y, III, IR * | respiratory failure | pleural empyema |
| F, 3.0 y, III, IR ** | respiratory failure | subglottic stenosis (recurrence post-extubation stenosis) |
| (2 PICU admissions) | respiratory failure | subglottic stenosis (recurrence post-extubation stenosis) |
| F, 7.1 y, III, HR (BP) * | neurological failure | intracranial hemorrhage (thrombocytopenia) |
| F, 3.3 y, IV (lung, bone), IR * | neurological failure | raised ICP leptomeningeal secondary malignancy |
| F, 1.5 y, IV (lung), IR * | respiratory failure | influenza A and post-irradiation ARDS |
| F, 4.9 y, IV (lung, liver), HR (DA) | circulatory failure | sepsis, chylothorax, chyloperitoneum |
| M, 1.8 y, IV (lung), bilateral, IR ** | circulatory failure | cardiomyopathy |
| (3 PICU admissions) | kidney injury | prerenal kidney injury (vomiting, gastric ulcer) in setting of CKD |
| | kidney injury | prerenal kidney injury (vomiting) in setting of CKD |
| F, 7 mo, V, IR, WT1 mutation | respiratory failure, kidney injury | suspected viral airway infection, ESDR with fluid overload |
| M, 4.3 y, V, HR (BP), hemihypertrophy ** | respiratory failure, kidney injury | ESKD with fluid overload, neutropenic sepsis |
| (3 PICU admissions) | neurological failure | seizures secondary to malignant hypertension and hypokalemia |
| | circulatory failure | massive bowel ischemia in setting of IRIS |

** 3.4. PICU Stay Characteristics**

The median PIM2 score was 1.0 (IQR 0.5–1.38; range 0.1–18.9) for unplanned PICU admissions during the disease course (n = 9 patients). ** Total of 3 unplanned PICU admissions during the disease course (n = 4 patients). PICU: pediatric intensive care unit, F: female, M: male, y: years, mo: months, LR: low risk, IR: intermediate risk, HR: high risk, BP: blastemal predominant, DA: diffuse anaplasia, WT: Wilms tumor, TSC1: tuberous sclerosis complex 1, GA: gestational age, ARDS: acute respiratory distress syndrome, TN: tumor nephrectomy, NSS: nephron sparing surgery, SMA: superior mesenteric artery, BPD: bronchopulmonary disease, IVC: inferior vena cava, RA: right atrium, ICP: intracranial pressure, CKD: chronic kidney disease, ESKD: end-stage kidney disease, IRIS: immune reconstitution inflammatory syndrome.
sion, acute kidney injury, syndrome of inappropriate ADH secretion (SIADH), Klebsiella pyelonephritis, and invasive candidiasis. The second, an 18-month-old girl with stage IV WT, was admitted for respiratory insufficiency secondary to combined influenza A and post-irradiation ARDS, requiring high-frequency oscillation (HFO), inhaled NO, inotropic support, and prolonged ventilatory support. The third, a 4-year-old boy with stage V high risk WT, was admitted for respiratory insufficiency secondary to neutropenic sepsis and concurrent end-stage kidney disease (ESKD), requiring 91 days of invasive ventilatory support, tracheostomy, and renal replacement therapy. The PICU admission was complicated by a tension pneumothorax, an intrathoracic hematoma requiring surgical intervention, S. Aureus sepsis, and invasive candidiasis.

Table 3. Characteristics of PICU admissions in children with WT.

|                              | Planned PICU Admissions (n = 70 Admissions) | Unplanned PICU Admissions (n = 50 Admissions) |
|------------------------------|--------------------------------------------|-----------------------------------------------|
| **Length of stay**           |                                             |                                               |
| LOS in days, median (IQR)    | 1.0 (1.0–1.0)                              | 3.0 (1.0–6.0)                                 |
| LOS in days, range           | <1–6                                       | <1–100                                        |
| **PIM2 score**               |                                             |                                               |
| PIM2 score, mortality probability %, median (IQR) | 0.25 (0.2–0.57) | 1.0 (0.5–1.38)                               |
| PIM2 score, mortality probability %, range   | 0.1–2.4                                    | 0.1–18.9                                      |
| **Invasive ventilation, n (%)** | 23 (32.9)                                  | 25 (50.0)                                     |
| Days on invasive ventilation, median (IQR)   | 0.1 (0.1–0.2)                              | 4.0 (1.0–1.5)                                 |
| Days on invasive ventilation, range         | 0.1–2                                      | <1–91                                         |
| **Vasopressor/inotropic support, n (%)**    | 1 (1.4)                                    | 14 (28.0)                                     |
| Days on vasopressor/inotropic support, median (IQR) | (-)                                        | 1.0 (0.3–1.0)                                 |
| Days on vasopressor/inotropic support, range | <1                                         | <1–4                                         |
| ECMO, n (%)                   | 0                                          | 0                                             |
| iNO, n (%)                    | 0                                          | 1 (2.0)                                       |
| **Renal replacement therapy, n (%)**        | 2 (2.8)                                    | 4 (8.0)                                       |
| Days on renal replacement therapy, range   | 2                                          | 2–47                                          |
| Renal replacement therapy at discharge, n (%) | 2 (2.8)                                    | 3 (9.1)                                       |
| **PICU mortality, n (%)**      | 0                                          | 2 (4.0)                                       |

* Insufficient data to compute PIM2 in 17 admissions. LOS: length of stay, PIM: Pediatric Index of Mortality, IQR: interquartile range, ECMO: extracorporeal membrane oxygenation, iNO: inhaled nitric oxide.

PICU resource use was significantly higher in the WT patients with an unplanned PICU admission compared to planned admissions. Twenty-five unplanned PICU cases (50%) required invasive mechanical ventilation, 14 cases (28%) required vasopressor and/or inotropic support, and four cases (8%) needed continuous renal replacement therapy. During three admissions, occurring in two bilateral WT patients, continued hemodialysis and peritoneal dialysis were needed, respectively, at PICU discharge because of tumor and treatment-related ESKD, of which one patient had germline WT1 mutation, without glomerulosclerosis in the remnant normal kidney tissue compartment.

Two children died during PICU stay. The first, a five-year-old boy receiving postoperative treatment for bilateral WT while on peritoneal dialysis for ESKD, died from circulatory insufficiency secondary to massive bowel ischemia attributed to invasive candidiasis with immune reconstitution inflammatory syndrome. The second, a three-year-old girl, died during postoperative treatment for lung and bone metastasized WT, local stage III. She died from increased intracranial pressure due to a concomitant leptomeningeal rhabdomyosarcoma, which was identified only during treatment as a secondary malignancy [24].

3.5. Outcome of WT Patients

Outcomes of the patients are depicted in Table 4. Median follow-up time was 52 months (IQR 30–115 months). At last follow-up, hypertension and renal function impairment CKD stage ≥ 2 was found to be more frequent in the survivors of unplanned PICU admitted patients when compared to the control group (p = 0.010 and p < 0.001, respec-
Five patients revealed CKD stage ≥3 renal function impairment after unplanned PICU admission, compared to no patient in the control group. Of these five patients, two developed ESKD. No differences were found for cardiac morbidity between patients after unplanned PICU admission and the control group. In addition, no significant differences of occurrence of relapse/refractory disease were found between both groups. Death was reported in six of 175 (3.4%) patients. Three patients died in the control group, due to tumor-related causes. Of the three patients that died in the unplanned PICU admission group, two children died during PICU stay from treatment-related toxicity and a secondary malignancy, respectively, and one patient had a tumor-related death during follow-up (relapsed WT).

Table 4. Outcome of children with WT.

| Follow-up time in months, median (IQR) | Total Cohort (n = 175 Patients) | Control Group (No or Planned PICU Admissions Only) (n = 142 Patients) | Unplanned PICU Admission (n = 33 Patients) |
|---------------------------------------|---------------------------------|-------------------------------------------------|------------------------------------------|
|                                      | 52 (30–115)                     | 52 (31–124)                                     | 50 (21–85)                               |
| Hypertension, n (%)                   |                                 |                                                 |                                          |
| At end of treatment                   | 13 (7.4)                        | 7 (4.9)                                         | 6 (18.2) †                               |
| At last follow-up                     | 12 (6.9)                        | 6 (4.2)                                         | 6 (18.2) †                               |
| Impaired renal function, n (%)        |                                 |                                                 |                                          |
| Any at end of treatment               | 6 (3.4)                         | 1 (0.7)                                         | 5 (15.2) †                               |
| CKD stage ≥2 at end of treatment      | 6 (3.4)                         | 1 (0.7)                                         | 5 (15.2) †                               |
| CKD stage ≥3 at end of treatment      | 4 (2.3)                         | 0 (0)                                           | 4 (12.1) †                               |
| Any at last follow-up                 | 15 (8.6)                        | 10 (7.0)                                        | 5 (15.2) †                               |
| CKD stage ≥2 at last follow-up        | 12 (8.9)                        | 7 (4.9)                                         | 5 (15.2) †                               |
| CKD stage ≥3 at last follow-up        | 5 (2.8)                         | 0 (0)                                           | 5 (15.2) †                               |
| Dialysis, n (%)                       |                                 |                                                 |                                          |
| At end of treatment                   | 2 (1.1)                         | 0 (0)                                           | 2 (6.1)                                  |
| At last follow-up                     | 1 (0.6)                         | 0 (0)                                           | 1 (3.0)                                  |
| Kidney transplant, n (%)              | 1 (0.6)                         | 0 (0)                                           | 1 (3.0)                                  |
| Cardiomyopathy, n (%)                 |                                 |                                                 |                                          |
| At end of treatment                   | 2 (1.1)                         | 1 (0.7)                                         | 1 (3.0)                                  |
| At last follow-up                     | 3 (1.7)                         | 2 (1.4)                                         | 1 (3.0)                                  |
| Relapse/Refractory WT, n (%)          |                                 |                                                 |                                          |
| Relapsed WT                           | 11 (6.3)                        | 8 (5.6)                                         | 3 (9.1)                                  |
| Refractory WT                         | 4 (2.3)                         | 3 (2.1)                                         | 1 (3.0)                                  |
| Time to relapse/progression in months, median (IQR) | 16.0 (8–30.5) | 15.5 (6.5–27) | 30.5 (8.5–30.5) |
| Overall mortality, n (%)              |                                 |                                                 |                                          |
| Time to death in months, median (IQR) |                                 |                                                 |                                          |
| Cause of death, n (%)                 | 6 (3.4)                         | 3 (2.1)                                         | 3 (9.1) †                               |
| - Tumor-related                       | 20.5 (8–26.5)                   | 26.5 (21.5–26.5)                                | 9.5 (6.5–9.5)                            |
| - Treatment-related                   | 4 (2.3)                         | 3 (2.1)                                         | 1 (3.0)                                  |
| - Secondary malignancy                | 1 (0.6)                         | 0 (0)                                           | 1 (3.0)                                  |

PICU: pediatric intensive care unit, IQR: interquartile range, WT: Wilms tumor, CKD stage: chronic kidney disease according to KDIGO: Kidney Disease–Improving Global Outcomes classification, GFR: glomerular filtration rate, † statistically significant difference p < 0.05.

4. Discussion
To the best of our knowledge, this is the first multi-center cohort study describing the frequency, admission indications, and outcome of Wilms tumor patients requiring PICU admission during the course of the disease. In general, current treatment strategies
result in excellent survival rates for most children with WT, and therefore, gaining insight into critical events is essential. Our study shows that almost 20% of children with WT require unplanned PICU admission during the course of first-line treatment and follow-up, of which one-third is before the start of any treatment as a result of tumor-related complications. Although 50% of patients with unplanned PICU admissions require invasive ventilatory support, most unplanned PICU admissions in this cohort had a relatively uncomplicated course, reflected in a short PICU length of stay, short ventilation duration, and short duration of inotropic support.

Interestingly, already during the diagnostic and preoperative chemotherapy treatment phase, serious tumor-related complications led to unplanned PICU admissions, with hypertension and respiratory failure due to large abdominal mass as the most prevalent causes of unplanned PICU admission. Hypertension is mainly based on activation of the renin-angiotensin aldosterone system (RAAS) by renin overproduction, in WT caused by local kidney ischemia due to vascular compression by large tumors, as well as directly by the blastemal component of the WT [25,26]. Untreated hypertension increases the risk of complications like cardiac decompensation, neurological deficits, and bleeding before or during renal surgery [26–28]. Whether a relatively short duration of tumor-related hypertension in WT patients may lead to long term adverse outcomes has not been sufficiently studied as yet. Previous studies have shown that more than half of WT patients suffer from hypertension at diagnosis, yet only 60% of these patients receive antihypertensive treatment [26,29]. The majority of children that received antihypertensive treatment were normotensive prior to surgery [26,29]. In our population, 4% (7/175) of children with WT required PICU admission for hypertension, with three of these seven during the preoperative chemotherapy phase. Potentially, early identification and treatment of hypertension with ACE inhibition may prevent the need for PICU admission and decrease the risk of hypertension-related complications. However, ACE-inhibition may also cause acute kidney injury in a kidney with diminished arterial flow due to compression caused by a tumor.

In the later treatment phase, PICU admission reasons were more diverse. In the general population of children with cancer requiring PICU admission, 12–38% of PICU admissions are due to sepsis, with a 50% PICU mortality rate [30,31]. In our cohort, there were few infectious complications leading to unplanned PICU admission, reflecting the generally lower intensity and consequent hematological toxicity of most WT treatment regimens when compared to the regimens required for, e.g., hematological malignancies. This may in part explain the low PICU mortality of 4% in this cohort, as compared to a 28% PICU mortality rate that has been reported in pooled cohorts of pediatric cancer patients [7].

Our study suggests that young and high-risk WT patients who receive intensive treatment regimens (i.e., for bilateral WT) seem to require unplanned PICU admission more often. This finding has not been described previously and is not consistently reflected in the previously reported cases of WT patients with complications requiring PICU admission [8–18]. In the SIOP93-01 and SIOP2001 studies, patients aged 6 months to 2 years were shown to have an excellent survival, with a higher event-free survival when compared to older age groups [2,3,32]. However, the results of our study show that, despite their superior survival outcome, young WT patients may carry a higher risk for treatment- and tumor-related complications leading to unplanned PICU admission in first-line treatment. It is conceivable that infants are more vulnerable to side effects of cytotoxic treatment. For that reason, dose adjustments are included in upfront treatment protocols [6]. Historically, excess complications and toxic deaths in infants treated in the first two National Wilms Tumor Study Group (NWTS) trials warranted a 50% chemotherapy dose reduction [33,34]. Similarly, following the International Society of Pediatric Oncology (SIOP) 6 study, unacceptable toxicity in infants led to a recommended chemotherapy reduction to 2/3 of the dose in infants and children with a body weight under 12 kg treated according to SIOP protocols [35]. Nevertheless, international consensus on how to adjust dosages in young children across all tumor types, based on pharmacokinetic research findings, is still pending. With regard to surgical complications, available evidence shows that surgical complications after primary nephrectomy for Wilms tumor are rare, and age was not found as a
risk factor [36]. In line with these findings, of the 14 patients who were admitted to PICU due to post-operative complications, only four were under two years of age.

Children with bilateral WT tumors are particularly at risk for critical illness, based on often intensive and prolonged treatment, as well as because of the requirement of resection of a considerable proportion of the healthy renal parenchyma. In addition, in a proportion of children, kidney disease caused by germline WT1 mutations can intrinsically already contribute to organ failure [37].

Despite the relatively uncomplicated admission course of the majority of unplanned PICU admissions in this cohort, a strikingly higher frequency of hypertension and chronic kidney disease was found at end of treatment and last follow-up in these patients compared to the control group. Chronic kidney disease stage ≥3 renal impairment was exclusively seen in unplanned PICU admitted patients, with ESKD occurring in two patients, both with bilateral WT, of which one had a WT1 gene variant. Hypertension and renal function impairment are well-known long-term morbidities following WT treatment [38,39]. Known risk factors include nephrectomy, bilateral WT, specific cytotoxic agents such as platinum-based and alkylating agents, and radiation therapy involving the kidney region [40,41]. Whether complications warranting PICU admission and the subsequent PICU treatment are also risk factors for adverse renal outcomes, or whether this is related to the clinical and disease characteristics of the WT patients in this group, remains the question.

Surprisingly, two patients presented with post-extubation subglottic stenosis after Wilms tumor surgery. One patient, who was born at 33 weeks, presented with an antenatal WT. This patient was intubated immediately after birth. The post-extubation subglottic stenosis was probably due to an intubation trauma. The second patient was 3 years old, with no reported pre-operative respiratory complaints. After the planned surgery, the patient was respiratory insufficient after extubation. This turned out to be due to subglottic stenosis. A cause of this stenosis has not been found. We do not expect it is a complication of the vincristine administration because pre-operative, no signs of upper respiratory tract obstruction were noted.

This study is the first to describe PICU admissions in a reasonably sized, unbiased cohort of WT patients at five tertiary pediatric oncology centers. However, we also acknowledge several limitations. An inherent limitation of this study is its retrospective nature, and the fact that we rely on data that were collected from patients’ medical records primarily captured for clinical care and not for research. This descriptive cohort study is insufficiently powered to allow multivariable regression analyses to model risk factors for unplanned PICU admission and outcome. Also, further studies are required to determine whether the higher frequency of hypertension at diagnosis as well as renal function impairment observed in WT patients requiring unplanned PICU admission is the result of ICU treatment complications or related to patient characteristics requiring more intensive treatment or predisposing to renal toxicity. This study was not designed to create general guidelines, as local resource issues and indications for PICU admission may vary between different countries and may depend on variation in general/ environmental circumstances over time, such as the recent COVID pandemic.

Our study on critical illness in children with WT illustrates the importance of multi-disciplinary specialized expert-centered care for children with renal tumors, as pointed out in the ExPO-R-Net initiative [6]. Accordingly, in the Netherlands, children with WT have been treated in specialized pediatric oncology centers over the last decades, and now, since November 2014, in only one dedicated national pediatric oncology center, by which we intend to increase survival and to increase quality of cure. Other initiatives will need to focus on more targeted effective, and less toxic, treatment modalities, to ultimately improve outcome by enhanced efficacy as well as decrease of treatment-related complications, especially in very young and intensively treated high-risk children.
5. Conclusions
In this multicenter study, with more than 15 years of inclusion, we observed that almost 20% of children with Wilms tumor required unplanned PICU admission, with young age and treatment intensity as potential risk factors. Hypertension and CKD stage 2 or higher was more frequently observed in unplanned PICU admitted patients, which justifies special attention for kidney function, development of proteinuria, and blood pressure monitoring during and after treatment of these children. Larger cohort studies are required to identify independent determinants of PICU admission and to clarify the role of events during PICU admission as a risk factor for hypertension and CKD as late morbidity in children with WT.

Author Contributions: Conceptualization, A.S., P.A.M.A.R.-J., M.M.v.d.H.-E. and R.M.W.-v.A.; methodology, A.S., P.A.M.A.R.-J., M.M.v.d.H.-E. and R.M.W.-v.A.; formal analysis, A.S., H.v.T. and P.A.M.A.R.-J.; data-extraction A.S., M.C.J.K., S.D., J.B.M.v.W. and D.A.v.W.; data curation, A.S. and P.A.M.A.R.-J.; writing—original draft preparation, A.S.; writing—review and editing, P.A.M.A.R.-J., M.M.v.d.H.-E., M.R.L., R.M.W.-v.A., C.P.v.d.V., A.F.W.v.d.S., M.W., R.R.d.K., H.v.T., A.S.L., G.O.J., A.M.L.P., G.A.M.T., A.M.M.-G. and M.v.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the Princess Máxima Center (MREC protocol n. 19/323).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data underlying this article may be shared on request to the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Pastore, G.; Znaor, A.; Spreafico, F.; Graf, N.; Pritchard-Jones, K.; Stelianova-Foucher, E. Malignant renal tumours incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 2006, 42, 2103–2114. [CrossRef] [PubMed]
2. De Kraker, J.; Graf, N.; van Tinteren, H.; Pein, F.; Sandstedt, B.; Godzinski, J.; Tournade, M.F. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms’ tumour (SIOP 93-01 trial): A randomised controlled trial. Lancet 2004, 364, 1229–1235. [CrossRef]
3. Pritchard-Jones, K.; Bergeron, C.; de Camargo, B.; van den Heuvel-Eibrink, M.M.; Acha, T.; Godzinski, J.; Oldenburger, F.; Boccon-Gibod, L.; Leuschner, I.; Vujanic, G., et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms’ tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial. Lancet 2015, 386, 1156–1164. [CrossRef]
4. Van den Heuvel-Eibrink, M.M.; van Tinteren, H.; Bergeron, C.; Coulomb-L’Hermine, A.; de Camargo, B.; Leuschner, I.; Sandstedt, B.; Acha, T.; Godzinski, J.; Oldenburger, F.; et al. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). Eur. J. Cancer 2015, 51, 498–506. [CrossRef] [PubMed]
5. Dome, J.S.; Graf, N.; Geller, J.I.; Fernandez, C.V.; Mullen, E.A.; Spreafico, F.; Van Den Heuvel-Eibrink, M.; Pritchard-Jones, K. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J. Clin. Oncol. 2015, 33, 2999–3007. [CrossRef]
6. Van den Heuvel-Eibrink, M.M.; Hol, J.A.; Pritchard-Jones, K.; van Tinteren, H.; Furtwangler, R.; Verschuur, A.C.; Vujanic, G.M.; Leuschner, I.; Brok, J.; Rube, C.; et al. Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat. Rev. Urol. 2017, 14, 743–752. [CrossRef]
7. Wösthen-van Asperen, R.M.; van Gestel, J.P.; van Grotel, M.; Tschießl, E.; Dohna-Schwake, C.; Valla, F.V.; Willems, J.; Anggaard Nielsem, J.S.; Krause, M.F.; Potratz, J.; et al. PICU mortality of children with cancer admitted to pediatric intensive care unit: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2019, 142, 153–163. [CrossRef]
8. Kajal, K.; Munirathinam, G.; Mandal, B.; Gandhi, K.; Singh, H.; Kanoja, R. Wilm’s tumor with intracardiac extension causing dynamic tricuspid valve obstruction: An anesthetic challenge. Saudi J. Anaesth. 2018, 12, 321–323. [CrossRef]
9. Chalavon, E.; Lampin, M.E.; Lervat, C.; Leroy, X.; Bonneville, M.; Recher, M.; Sudour-Bonnange, H. Dilated Cardiomyopathy Caused by Wilms Tumor. Pediatr. Emerg. Care 2017, 33, 41–42. [CrossRef]
10. Abraham, M.; Samuel, M.; Mathew, M. Wilms tumour with intracardiac extension–multimodal approach to a challenging case. *Indian J. Anaesth.* 2016, 60, 216–218. [CrossRef]

11. Dhar, M.; Prakash, S.; Pandey, V.; Fai, V. Intraoperative tumor lysis syndrome in a child with Wilms’ tumor. *Anesth. Essays Res.* 2016, 10, 145–147. [CrossRef] [PubMed]

12. Genc, D.B.; Vural, S.; Telhan, L. Wilms Tumor Presenting with Fulminating Hepatic Failure and Succesful Initial Treatment with Cyclophosphamide. *Pediatr. Blood Cancer* 2016, 63, 177–178. [CrossRef] [PubMed]

13. Li, L.; Light, J.; Marchick, M.; Hoelle, R. Dyspnea, Tachycardia, and New Onset Seizure as a Presentation of Wilms Tumor: A Case Report. *Case Rep. Emerg. Med.* 2014, 2014, 562672. [CrossRef] [PubMed]

14. Martín-Lázaro, J.F.; Palanca, D.; García-Iñiguez, J.P.; Madurga, P.; Carboné, A. Hepatopathy-thrombocytopenia syndrome after actinomycin-D therapy: Treatment with defibrotide. *Pediatr. Hematol. Oncol.* 2013, 30, 25–27. [CrossRef]

15. Cooper, L.; Moore, C.; Branchford, B.; Greffe, B.; Capocelli, K.; Kuder, A.; Mehta, I.; Mourani, P.M. Successful Pulmonary Artery Embolectomy in a Patient with a Saddle Wilms Tumor Embolus. *Pediatr. Blood Cancer* 2012, 58, 806–809. [CrossRef]

16. Dressler, A.M.; Finck, C.M.; Carroll, C.L.; Bonanni, C.C.; Spinella, P.C. Use of a massive transfusion protocol with hemostatic resuscitation for severe intraoperative bleeding in a child. *J. Pediatr. Surg.* 2010, 45, 1530–1533. [CrossRef]

17. Nagappa, M.; Bhat, R.R.; Sudeep, K.; Mishra, S.K.; Badhe, A.S.; Hemavathi, B. Vincristine-induced acute life-threatening hyponatremia resulting in seizure and coma. *Indian J. Crit. Care Med.* 2009, 13, 167–168.

18. Van Toorn, R.; Wessels, G.; Stefan, C. Catastrophic intracerebral hemorrhage in a young infant with Wilms tumor. *J. Pediatr. Hematol. Oncol.* 2007, 29, 29–300. [CrossRef]

19. Vujanić, G.M.; Sandstedt, B.; Harms, D.; Leuschner, I.; Kelsey, A.; de Kraker, J. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. *Med. Pediatr. Oncol.* 2002, 38, 79–82. [CrossRef]

20. Slater, A.; Shann, F.; Pearson, G. PIM2: A revised version of the Paediatric Index of Mortality. *Intensive Care Med.* 2003, 29, 278–285. [CrossRef]

21. Alexander, S.; Pole, J.D.; Gibson, P.; Lee, M.; Hesser, T.; Chi, S.N.; Hesser, T.; Kanerva, J.; et al. Classification of treatment-related mortality in children with cancer: A systematic assessment. *Lancet Oncol.* 2015, 16, e604–e610. [CrossRef]

22. Flynn, J.T.; Kaelber, D.C.; Baker-Smith, C.M.; Blowey, D.; Carroll, A.E.; Daniels, S.R.; De Ferranti, S.D.; Dionne, J.M.; Falkner, B.; Flinn, S.K.; et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics* 2017, 140, e20171904. [CrossRef] [PubMed]

23. Levin, A.; Stevens, P.E.; Bilous, R.W.; Coresh, J.; De Francisco, A.L.M.; De Jong, P.E.; Griffith, K.E.; Hemmelgarn, B.R.; Iseki, K.; Lamb, E.J.; et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int. Suppl.* 2013, 3, 1–150.

24. Roy, P.; van Peer, S.E.; de Witte, M.M.; Tytgat, G.A.M.; Karim-Kos, H.E.; van Grotel, M.; van de Ven, C.P.; Mavinkurve-Groothuis, A.M.C.; Merks, J.H.M.; Kuiper, R.P.; et al. Characteristics and outcome of children with renal tumors in the Netherlands: The first five-year’s experience of national centralization. *PLoS ONE* 2022, 17, e0261729. [CrossRef] [PubMed]

25. Voûte, P.A.; van der Meer, J.; Staugarda-Kloosterziel, W. Plasmin Renin Activity in Wilms Tumor. *Acta Endocrinol.* 1971, 67, 197–202. [CrossRef]

26. Maas, M.H.; Cransberg, K.; van Grotel, M.; Pieters, R.; van den Heuvel-Eibrink, M.M. Renin-Induced Hypertension in Wilms Tumor Patients. *Pediatr. Blood Cancer* 2007, 48, 500–503. [CrossRef]

27. Charlton, G.A.; Sedgwick, J.; Sutton, D.N. Anaesthetic Management of Renin Secreting Nephroblastoma. *Br. J. Anaesth.* 1992, 69, 206–209. [CrossRef]

28. Singh, D.; Akingbola, O.; Yosypiv, I.; El-Dahr, S. Emergency Management of Hypertension in Children. *Int. J. Nephrol.* 2012, 2012, 420247. [CrossRef]

29. Steinbrecher, H.A.; Malone, P.S. J. Wilms’ tumour and hypertension: Incidence and outcome. *Br. J. Urol.* 1995, 76, 241–243. [CrossRef]

30. Hallahah, A.R.; Shaw, P.J.; Rowell, G.; O’Connell, A.; Schell, D.; Gillis, J. Improved outcomes of children with malignancy admitted to a pediatric intensive care unit. *Crit. Care Med.* 2000, 28, 3718–3721. [CrossRef]

31. Abraham, R.B.; Toren, A.; Ono, N.; Weinbroum, A.A.; Vardi, A.; Barzilay, Z.; Paret, G. Predictors of outcome in the pediatric intensive care units of children with malignancies. *J. Pediatr. Hematol. Oncol.* 2012, 24, 23–26. [CrossRef]

32. Hol, J.A.; Lopez-Yurda, M.I.; Van Tinteren, H.; Van Grotel, M.; Godzinski, J.; Vujanic, G.; Oldenburger, F.; De Camargo, B.; Ramirez-Villar, G.L.; Bergeron, C.; et al. Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric oncology (SIOP) 93-01 and 2001. *PLoS ONE* 2019, 14, e0221373. [CrossRef]

33. Breslow, N.E.; Palmer, N.F.; Hill, L.R.; Buring, J.; D’Angio, G.J. Wilm’s tumor: Prognostic factors for patients without metastases at diagnosis: Result of the National Wilms’ Tumor Study. *Cancer* 1978, 41, 1577–1589. [CrossRef]

34. Jones, B.; Breslow, N.E.; Takahashi, J. Toxic deaths in the second National Wilms’ Tumor Study. *J. Clin. Oncol.* 1984, 2, 1028–1033. [CrossRef]

35. Coppes, M.J.; Tournade, M.F.; Lemjer, J.; Weitzman, S.; Rey, A.; Burger, D.; Carl, M.; Voûte, P.A. Preoperative Care of Infants with Nephroblastoma: The International Society of Pediatric Oncology 6 Experience. *Cancer* 1992, 69, 2721–2725. [CrossRef] [PubMed]

36. Ritchey, M.L.; Shamberger, R.C.; Haase, G.; Horwitz, J.; Bergemann, T.; Breslow, N.E. Surgical complications after primary nephrectomy for Wilms’ tumor: Report from the National Wilms’ Tumor Study Group. *J. Am. Coll. Surg.* 2001, 192, 63–68. [CrossRef]
37. Charlton, J.; Irtan, S.; Bergeron, C.; Pritchard-Jones, K. Bilateral Wilms tumour: A review of clinical and molecular features. *Expert Rev. Mol. Med.* **2017**, *19*, e8. [CrossRef] [PubMed]

38. Neu, M.A.; Russo, A.; Wingerter, A.; Alt, F.; Theruvath, J.; El Malki, K.; Kron, B.; Dittrich, M.; Lotz, J.; Stein, R.; et al. Prospective analysis of long-term renal function in survivors of childhood Wilms tumor. *Pediatr. Nephrol.* **2017**, *32*, 1915–1925. [CrossRef] [PubMed]

39. Mavinkurve-Groothuis, A.M.; van de Kracht, F.; Westland, R.; van Wijk, J.A.; Loonen, J.J.; Schreuder, M.F. Long-term follow-up of blood pressure and glomerular filtration rate in patients with a solitary functioning kidney: A comparison between Wilms tumor survivors and nephrectomy for other reasons. *Pediatr. Nephrol.* **2016**, *31*, 435–441. [CrossRef]

40. Dekkers, I.A.; Blijdorp, K.; Cransberg, K.; Pluijm, S.M.; Pieters, R.; Neggers, S.J.; van den Heuvel-Eibrink, M.M. Long-Term nephrotoxicity in adult survivors of childhood cancer. *Clin. J. Am. Soc. Nephrol.* **2013**, *8*, 922–929. [CrossRef]

41. Kooijmans, E.C.; Bökenkamp, A.; Tjahjadi, N.S.; Tettero, J.M.; van Dulmen-den Broeder, E.; van der Pal, H.J.H.; Veening, M.A. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. *Cochrane Database Syst. Rev.* **2019**, *3*, CD008944. [CrossRef] [PubMed]